Invicta Diagnostic NSE SME

Invicta Diagnostic SME IPO

Listed

NSE SMEOpens 1 December 2025Closes 3 December 2025

Invicta Diagnostics (PC Diagnostics) is a diagnostic chain operating primarily in the Mumbai Metropolitan Region (MMR). The company provides a one-stop solution by offering both radiology (X-ray, CT, MRI, PET CT) and…

Show more
Price band
₹80 - ₹85
Issue size
₹28.12 Cr
Lot size
1,600 shares
Type
NSE SME
GMP
₹0 (0.0%)
Est. listing
₹85
Est. profit / app
—
Retail quota
38.30%

Key ratios

As per RHP / filings
Face value
₹10
EPS
6.5
P/E ratio
13.08
RoNW
36.25%
ROE
44.28%
Debt / Equity
0.26
Advertisement

Timeline

  1. IPO Opens

    1 Dec 2025

  2. IPO Closes

    3 Dec 2025

  3. Allotment

    4 Dec 2025

  4. Listing

    8 Dec 2025

IPO Timeline & Listing Details

EventDate
IPO Open Date1 December 2025
IPO Close Date3 December 2025
Allotment Date4 December 2025
Listing Date8 December 2025

Investment Categories

CategoryLotsAmount
Individual
2₹2,72,000
SHNI (Min)
3₹4,08,000
SHNI (Max)
7₹9,52,000
BHNIAbove ₹10,00,000
8₹10,88,000

IPO Reservation Details

CategoryReservation
QIB (Qualified Institutional Buyer)40.28%
NII (Non-Institutional Investor)16.39%
SHNI (Small Non-Institutional Investor)5.46%
BHNI (Big Non-Institutional Investor)10.93%
Retail38.30%
Market Maker5.03%
Total100.00%

IPO Objectives

  • Funding capital expenditure for purchase of medical equipment towards establishment of five new diagnostic centres in Maharashtra (₹21.11 Cr).
  • General Corporate Purposes.

Strengths

  • The company offers a one-stop solution for both advanced radiology and pathology services, which minimizes patient referral needs.
  • It is expanding its presence in the high-growth radiology sector within the Mumbai Metropolitan Region (MMR).
  • The implementation of a Hub and Spoke Model enables wide customer reach and promotes operational efficiency across the MMR.
  • The business shows strong financial growth, with Revenue increasing by 90% and PAT rising by 30% between FY24 and FY25.
  • It maintains excellent profitability metrics with an RoNW of 36.25% and a high PAT margin of 16.34% in FY25.

Weaknesses

  • The company faces a high capital expenditure requirement for new centers and equipment, subjecting it to execution risk and long gestation periods.
  • It operates in a market with intense competition from larger national and regional players in the MMR, leading to pricing pressure.
  • The business has a high dependency on the availability and maintenance of expensive medical equipment (CT, MRI, PET CT).
  • There is geographic concentration in the MMR, making the business vulnerable to regional economic and competitive factors.
  • The working capital intensive nature of operations requires continuous investment to support growth.
Advertisement

Financial Performance

Period Ended30 Sep 202531 Mar 202531 Mar 2024
Assets (₹ Cr.)34.921.2215.89
Revenue (₹ Cr.)17.0830.1815.9
PAT (₹ Cr.)4.084.933.81
Net Worth (₹ Cr.)23.6813.68.67

Peer Comparison

CompanyP/B RatioP/E RatioRONW (%)Net Worth (₹ Cr.)
Invicta Diagnostic Limited5.2613.0844.28%23.68
Vijaya Diagnostic11.8867.5817.53%799
Krsnaa Diagnostics2.8631.179.16%883

Subscription Details

Daily Bids Status

CategoryDay 1Day 2Day 3
QIB1x1.55x3.51x
NII0.68x0.74x6.96x
S-HNI0.45x0.58x6.27x
B-HNI0.79x0.81x7.3x
RII0.29x0.79x3.44x
Total0.54x0.95x4.27x

Overall Subscription Statistics

CategoryShares OfferedShares BidBid Amount (₹ Cr)
QIB5,34,40018,75,20015.94
NII5,42,40037,74,40032.08
Small NII1,80,80011,34,4009.64
Big NII3,61,60026,40,00022.44
RII12,67,20043,58,40037.05
Total23,44,0001,00,08,00085.07
Advertisement

Company Details

  • Invicta Diagnostic Ltd.
  • 1 GF, Plot 217, Ambavat Bhavan, N.M Joshi Marg, Delisle Road, Mumbai, -400013
  • 022 - 4971 0036
  • investors@pcdiagnostics.in
  • https://www.pcdiagnostics.in/

Registrar Details

Frequently Asked Questions

What diagnostic services does Invicta Diagnostic offer?
Invicta Diagnostic (PC Diagnostics) offers a complete range of radiology (CT, MRI, PET CT, X-ray) and pathology services (routine and specialized tests), following a one-stop solution model.
When will the Invicta Diagnostic IPO open for subscription?
The Invicta Diagnostic SME IPO opens for subscription on December 1, 2025, and closes on December 3, 2025.
What is the operating model of Invicta Diagnostic?
The company uses a Hub-and-Spoke model across the MMR, where Hubs provide advanced radiology and pathology, and Spokes handle pathology collection and basic radiology, ensuring a wide and convenient network.
What are the main objectives of the ₹26.71 Cr Fresh Issue?
The net proceeds are primarily for funding capital expenditure (₹21.11 Cr) to establish five new diagnostic centres in Maharashtra and for General Corporate Purposes.
What are the key financial strengths of Invicta Diagnostic?
Invicta Diagnostic has shown strong revenue growth (90% in FY25) and reports an excellent RoNW of 36.25% and a high PAT margin of 16.34%.
What is the IPO price band and listing date for Invicta Diagnostic?
The price band is ₹80.00 to ₹85.00 per share, and the tentative listing date on the NSE SME is December 8, 2025.

Invicta Diagnostic SME IPO News & Updates

Follow the latest updates for Invicta Diagnostic SME IPO, including grey market moves and allotment news.

Invicta Diagnostic SME IPO IPO Pages

Open related pages for this IPO: details, GMP, subscription, allotment, review, FAQ, registrar, timeline, and news.

Sources

We match Invicta Diagnostic SME IPO IPO numbers with official sources. For final dates and allotment results, double-check the registrar or exchange.

  • SEBIRules for IPO allotment and disclosures in India
  • NSEExchange notices, bidding data, and listing updates
  • BSEExchange notices and IPO allotment check tools
  • RHP / Offer DocumentCheck the company RHP on NSE/BSE or the IPO detail page
  • Bigshare Services Pvt.Ltd.Official site to check allotment status for this IPO

Also read our Editorial Policy, How GMP is calculated, How allotment chances work, and IPO fund allocation.

Reviewed by

Dinesh Agrawal · Lead IPO Analyst

15+ years in Indian markets and IPO research. He reviews IPO dates and key details before they go live.

Loading comments...